Replies to post #486576 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

Patients in the PIII trial did not get doses for 5 years, rather 10 doses in total over 3 years, so these numbers you cite are not accurate. I believe Ashkan said that rGBM results were great despite not having additional doses after tumor occurrence. So you are overstating the amount of doses needed.

Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.

https://clinicaltrials.gov/ct2/show/NCT00045968#studydesign

Patients will receive either the study vaccine or a placebo over the course of 3 years and up to 10 injections.

https://www.uclahealth.org/neurosurgery/aphase-iii-clinical-trial-evaluating-dcvax


Obviously once produced DCVax will not cost 50K a year to keep frozen! These costs will be lower as economies of scale are much greater when the clean rooms are online post approval.

Moreover, NWBO will want to lower the price they charge to make NICE happy since the UK government has a lot of leverage to negotiate prices. So they won't ask for that much.

In summary your 350K number is outrageous and not based upon the doses given in our clinical trial nor any likely outcome. You can pad the numbers to further your argument but it's not a realistic scenario.